Coronavirus

Dr. Fauci on why the U.S. is ‘out of the pandemic phase’
Jul02

Dr. Fauci on why the U.S. is ‘out of the pandemic phase’

  Editor’s note: In speaking with The Washington Post after this interview, Dr. Anthony Fauci expanded on his remarks, saying that the U.S. was out of the “full-blown explosive pandemic phase,” but that the virus still posed a threat. “We’re really in a transitional phase, from a deceleration of the numbers into hopefully a more controlled phase and endemicity,” Fauci told the Post. TranscriptAudio As COVID...

Read More
COVID-19 Third Dose Vaccine Protection Against Hospitalization Wanes After 3 Months
Apr28

COVID-19 Third Dose Vaccine Protection Against Hospitalization Wanes After 3 Months

Kaiser Permanente finds the Pfizer COVID-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months. A research study released on April 22, 2022, in The Lancet Respiratory Medicine shows that a booster dose of the Pfizer COVID-19 vaccine provides strong protection, roughly 80% to 90%, in the first few months against hospital admissions and emergency department visits caused by the delta and omicron...

Read More
What Fauci sees coming with the BA.2 coronavirus subvariant in the U.S.
Apr10

What Fauci sees coming with the BA.2 coronavirus subvariant in the U.S.

The U.S. could follow the trend of the United Kingdom and see a surge in COVID-19 cases driven by the BA.2 subvariant of the coronavirus, according to Dr. Anthony Fauci. The chief medical adviser to President Biden said that though cases are still trending down across the U.S., some states are seeing a rise. “I think without a doubt that we are going to see a turnaround as people get out more and into the inside venues without...

Read More
NRx Pharma Reports US National Institutes Of Health Study Of Its ZYESAMI for COVID Cleared To Complete Full Enrollment
Feb26

NRx Pharma Reports US National Institutes Of Health Study Of Its ZYESAMI for COVID Cleared To Complete Full Enrollment

  – After review of more than 448 enrolled patients in ACTIV-3b Critical Care Study, no new safety concerns identified by Independent Data Safety Monitoring Board; study cleared to continue enrollment to 640 Patients – ZYESAMI® (aviptadil) is the sole remaining investigational medicine in ACTIV-3b with recent closures of other arms – ACTIV-3b Critical Care Study is evaluating ZYESAMI and Veklury® (remdesivir),...

Read More
Omicron Variant: What You Need to Know
Feb16

Omicron Variant: What You Need to Know

  Omicron in the United States CDC is working with state and local public health officials to monitor the spread of Omicron. As of December 20, 2021, Omicron had been detected in most states and territories and continues to be the dominant variant in the United States. What We Know about Omicron CDC has been collaborating with global public health and industry partners to learn about Omicron, as we continue to monitor its course....

Read More
Omicron variant of COVID-19 spreading at unprecedented levels in La Plata and Archuleta Counties
Jan23

Omicron variant of COVID-19 spreading at unprecedented levels in La Plata and Archuleta Counties

  San Juan Basin Public Health (SJBPH) is currently reporting more positive cases and transmission of COVID-19 than at any time during the nearly two-year pandemic. SJBPH attributes the local surge in cases to the highly transmissible Omicron variant. Questions remain about Omicron’s severity, and the impact on local COVID-19 hospitalizations will become clearer in the coming days and weeks. To preserve already strained health...

Read More
Massachusetts schools are using dogs to detect Covid-19
Jan15

Massachusetts schools are using dogs to detect Covid-19

(CNN)A Massachusetts school district has invited two new police officers to patrol its buildings, only these cops have four paws and aren’t detecting crime. They’re detecting Covid. A pair of specially-trained dogs, 14-month-old labs named Huntah and Duke, began their training in May 2021, and now roam the halls of schools in the Freetown-Lakeville Regional School District. The Bristol County Sheriff’s Office worked...

Read More
Do You Have A Winter Health Issue Or COVID-19? Here’s How To Tell.
Oct17

Do You Have A Winter Health Issue Or COVID-19? Here’s How To Tell.

  There are telltale signs that differentiate winter allergies from COVID-19. (Photo: Antonio_Diaz via Getty Images)   Ah, winter ― a time where we find ourselves constantly asking if we’re sick or if it’s just a reaction to the weather and all that comes with it. And during the coronavirus pandemic, those average winter symptoms feel even more alarming. “As we go into these winter months, symptoms may be due to different...

Read More
NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil)
Sep29

NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil)

   ZYESAMI™ (aviptadil) Has Previously Demonstrated a Statistically Significant Increase in Survival of Highly Comorbid COVID-19 Patients in Two 60-day Trials – In a Study of Highly Comorbid Patients, ZYESAMI Provided a Threefold, Statistically Significant Increase in Likelihood of Survival at One Year RADNOR, Pa., Sept. 27, 2021 /PRNewswire/ — NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage, biopharmaceutical...

Read More
Fauci ‘certain’ Americans will need COVID-19 booster shots
Aug29

Fauci ‘certain’ Americans will need COVID-19 booster shots

Dr. Anthony Fauci on Sunday said that he was “certain” that Americans would need booster shots of the COVID-19 vaccine but how long they’ll need to wait to get them could change. “I’m certain we’re going to need that third dose, looking at the data that we’re seeing,” the White House chief medical advisor said on NBC’s “Meet the Press.” Fauci said that the White House was moving ahead with plans to give out the boosters eight months...

Read More
A grim warning from Israel: Vaccination blunts, but does not defeat Delta
Aug21

A grim warning from Israel: Vaccination blunts, but does not defeat Delta

                “Now is a critical time,” Israeli Minister of Health Nitzan Horowitz said as the 56-year-old got a COVID-19 booster shot on 13 August, the day his country became the first nation to offer a third dose of vaccine to people as young as age 50. “We’re in a race against the pandemic.” His message was meant for his fellow Israelis, but it is a warning to the world. Israel has among...

Read More
Delta variant rises to dominance in La Plata, Archuleta counties
Aug07

Delta variant rises to dominance in La Plata, Archuleta counties

People who are unvaccinated experiencing surge of cases By Shannon Mullane Herald Staff Writer Saturday, Aug. 7, 2021 5:00 Vanessa Taylor, 47, said she is still monitoring her recovery from COVID-19 six weeks after her original diagnosis. She caught the virus from her daughter, Rhyse, 9. (Jerry McBride/Durango Herald) The headaches, coughing and body aches started in late June for Durango resident Vanessa Taylor. When she went to the...

Read More
NRx Pharmaceuticals Announces Emergency Use Authorization Of ZYESAMI In Nation Of Georgia
Jul28

NRx Pharmaceuticals Announces Emergency Use Authorization Of ZYESAMI In Nation Of Georgia

NRx Pharmaceuticals (NASDAQ:NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia’s Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous ZYESAMI™ (aviptadil) for the treatment of Critical COVID-19.   NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia “Lead investigators...

Read More
NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI, Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval
Jul22

NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI, Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval

NRx Pharmaceuticals (NRx) (NASDAQ:NRXP) announced today it has validated the first commercial formulation of ZYESAMI™ (aviptadil) for intravenous use, allowing for high volume manufacture, with an anticipated one year or greater stability, under appropriate storage conditions. Simultaneously, NRx has achieved a 30-to-50-fold increase in its manufactured lot size of aviptadil, with a concurrent 90% reduction in the cost of its peptide...

Read More
CDC Relaxes COVID-19 Mask Guidelines For Vaccinated Americans
May01

CDC Relaxes COVID-19 Mask Guidelines For Vaccinated Americans

The Centers for Disease Control and Prevention released new coronavirus guidelines for vaccinated Americans on Tuesday that include updated recommendations on mask-wearing while outdoors. The new guidance says people who have been fully vaccinated and have waited at least two weeks after their last shot do not need to wear masks outdoors when alone, with members of their household or in small gatherings. They may also forgo masks...

Read More
Relief Reports 2020 Financial Results and Provides Business Update
Apr16

Relief Reports 2020 Financial Results and Provides Business Update

GENEVA, SWITZERLAND / ACCESSWIRE / April 15, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (“Relief” or the “Company”), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial results for the year ended December 31, 2020 and provided a business update. “The past year...

Read More
RELIEF CONFIRMS RELEASE OF 60-DAY Findings
Apr13

RELIEF CONFIRMS RELEASE OF 60-DAY Findings

RELIEF CONFIRMS RELEASE OF 60-DAY FINDINGS FROM PHASE 2B/3 CLINICAL TRIAL OF INTRAVENOUS RLF-100™ (AVIPTADIL) 30 March 2021 60-day results have been presented by Relief’s partner, NeuroRx, Inc. Geneva, Switzerland, March 30, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief”), a biopharmaceutical company with its lead compound RLF-100™ (aviptadil) in advanced clinical development to treat critically-ill COVID-19...

Read More
Why has Covid’s toll been surprisingly low across much of Africa and Asia?
Mar10

Why has Covid’s toll been surprisingly low across much of Africa and Asia?

By David Leonhardt Good morning. Why has Covid’s toll been surprisingly low across much of Africa and Asia? ‘An epidemiological whodunit’ It’s one of the biggest mysteries about Covid-19: Why has the death toll been relatively low across much of Africa and Asia? The virus has killed a fraction of as many people on those continents — despite their relative lack of resources — as it has in Europe or the U.S.: This isn’t how public...

Read More
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19
Mar03

NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19

NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint NeuroRx to File for Emergency Use Authorization in This Patient Population if Positive Results Continue to be Demonstrated at Day-60 Endpoint in Line with FDA’s New Guidance NEWS PROVIDED BY NeuroRx ...

Read More
NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™
Feb09

NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™

NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19 If Authorized for Use, ZYESAMI™ Would be First Treatment Specifically for Critically Ill Patients with Respiratory Failure RADNOR, Pa. and GENEVA, Feb. 9, 2021 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings...

Read More